From observation to optimization: behavioral metrics that matter in KPI based home cage monitoring

Most <i>in vivo</i> scientists would agree that digital biomarkers collected via home-cage monitoring generate valuable data. However, few can tell precisely how valuable. The gap between enthusiasm and evidence has slowed the adoption of digital biomarkers in preclinical research. This framework paper addresses that gap by providing explicit key performance indicators (KPIs), organized into scientific, operational, welfare, and financial categories. We show how return-on-investment calculations differ across pharmaceutical companies, contract research organizations (CROs), and academic institutions. Furthermore, we demonstrate the approach through a worked example in an Amyotrophic Lateral Sclerosis (ALS) mouse model that reduces full-time equivalent (FTE) requirements by half. When successfully integrated, digital biomarkers can generate richer datasets, reduce the number of animals, improve welfare, and enhance translational value. However, successful implementation requires clear performance metrics to justify investment and measure success. We also discuss what these technologies cannot do, because understanding limitations matters as much as understanding benefits.

Authors

Institutions

Publication Details

Journal
Frontiers in Behavioral Neuroscience
Published
2026-03-02
DOI
https://doi.org/10.3389/fnbeh.2026.1694689
Primary Topic
Animal testing and alternatives
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From observation to optimization: behavioral metrics that matter in KPI based home cage monitoring

Stefano Gaburro, Marcel van Gaalen, Fabrizio Scorrano, Pierre Lainée et al.
Frontiers in Behavioral Neuroscience
Animal testing and alternatives
article

From observation to optimization: behavioral metrics that matter in KPI based home cage monitoring

Stefano Gaburro, Marcel van Gaalen, Fabrizio Scorrano, Pierre Lainée, Steven R. Talbot
article en

Abstract

Most <i>in vivo</i> scientists would agree that digital biomarkers collected via home-cage monitoring generate valuable data. However, few can tell precisely how valuable. The gap between enthusiasm and evidence has slowed the adoption of digital biomarkers in preclinical research. This framework paper addresses that gap by providing explicit key performance indicators (KPIs), organized into scientific, operational, welfare, and financial categories. We show how return-on-investment calculations differ across pharmaceutical companies, contract research organizations (CROs), and academic institutions. Furthermore, we demonstrate the approach through a worked example in an Amyotrophic Lateral Sclerosis (ALS) mouse model that reduces full-time equivalent (FTE) requirements by half. When successfully integrated, digital biomarkers can generate richer datasets, reduce the number of animals, improve welfare, and enhance translational value. However, successful implementation requires clear performance metrics to justify investment and measure success. We also discuss what these technologies cannot do, because understanding limitations matters as much as understanding benefits.

Frontiers in Behavioral NeuroscienceVol. 20
Novartis (Switzerland) (CH), Sanofi (France) (FR), Medizinische Hochschule Hannover (DE), Tecnalia (ES), Institute of Laboratory Animal Science (CN), Evotec (United States) (US)
Partnerships for the goals
Openalex Percentile: Top 36%
Animal testing and alternatives
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.